1162 related articles for article (PubMed ID: 27560276)
1. Stroke prevention in atrial fibrillation.
Freedman B; Potpara TS; Lip GY
Lancet; 2016 Aug; 388(10046):806-17. PubMed ID: 27560276
[TBL] [Abstract][Full Text] [Related]
2. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
3. Clinical Stroke prevention in atrial fibrillation.
Voukalis C; Shantsila E; Lip GY
J R Coll Physicians Edinb; 2017 Mar; 47(1):13-23. PubMed ID: 28569277
[TBL] [Abstract][Full Text] [Related]
4. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY
Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192
[TBL] [Abstract][Full Text] [Related]
5. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
6. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
7. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
[TBL] [Abstract][Full Text] [Related]
8. Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)?
Hung Y; Chao TF; Liu CJ; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Liao JN; Chung FP; Lin WY; Lin WS; Cheng SM; Chen TJ; Lip GY; Chen SA
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27702803
[TBL] [Abstract][Full Text] [Related]
9. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants.
Turagam MK; Velagapudi P; Flaker GC
Clin Interv Aging; 2015; 10():1431-44. PubMed ID: 26366064
[TBL] [Abstract][Full Text] [Related]
10. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
Potpara TS; Lip GY
Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
[TBL] [Abstract][Full Text] [Related]
11. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
Renda G; di Nicola M; De Caterina R
Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
[TBL] [Abstract][Full Text] [Related]
12. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.
Lip GY; Rushton-Smith SK; Goldhaber SZ; Fitzmaurice DA; Mantovani LG; Goto S; Haas S; Bassand JP; Camm AJ; Ambrosio G; Janský P; Al Mahmeed W; Oh S; van Eickels M; Raatikainen P; Steffel J; Oto A; Kayani G; Accetta G; Kakkar AK;
Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2 Suppl 1):S12-20. PubMed ID: 25714828
[TBL] [Abstract][Full Text] [Related]
13. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
[TBL] [Abstract][Full Text] [Related]
14. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.
Song HY; Son KB; Shin JY; Bae S
Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377
[TBL] [Abstract][Full Text] [Related]
15. Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage.
Chao TF; Liu CJ; Liao JN; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chen TJ; Lip GY; Chen SA
Circulation; 2016 Apr; 133(16):1540-7. PubMed ID: 26969761
[TBL] [Abstract][Full Text] [Related]
16. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
[TBL] [Abstract][Full Text] [Related]
17. Stroke prevention in atrial fibrillation: do we still need warfarin?
Diener HC; Weber R; Lip GY; Hohnloser SH
Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
[TBL] [Abstract][Full Text] [Related]
18. Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.
Zoppellaro G; Granziera S; Padayattil Jose S; Denas G; Bracco A; Iliceto S; Pengo V
Expert Opin Drug Saf; 2015 May; 14(5):683-95. PubMed ID: 25803739
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of the CHA
Jaakkola S; Kiviniemi TO; Nuotio I; Hartikainen J; Mustonen P; Palomäki A; Jaakkola J; Ylitalo A; Hartikainen P; Airaksinen KEJ
Am J Cardiol; 2018 May; 121(10):1182-1186. PubMed ID: 29526276
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Senoo K; Lip GY
Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
